Basis: Four-quarter operating EBITDA / current FMP quote-based enterprise value × 100. Source: stored company filings and market data; unavailable inputs remain N/A.
The EBITDA yield is N/A as of 2026-10-06T17:03:57.480Z.
Calculation as of: 2026-10-06T17:03:57.480Z.
Quote observation: 2026-10-06T17:00:52.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 24a0b8a5defa6360a8df5348432e42fec2fdf5a1d44ff9a0d63a76d612d48360
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
EBITDA YIELD
N/A
Market Cap
$1.09B
EBITDA Yield
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$1.11B
EBITDA Yield
4.43%
TTM Avg
1.74%
3Y Avg
1.95%
5Y Avg
1.61%
Market Cap
$1.13B
EBITDA Yield
11.26%
TTM Avg
12.87%
3Y Avg
11.35%
5Y Avg
9.45%
Market Cap
$1.13B
EBITDA Yield
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
| NAME | MARKET CAP | EBITDA YIELD | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Replimune Group, Inc. (REPL) | $1.10B | N/A | N/A | N/A | N/A |
| Bicara Therapeutics Inc. Common Stock (BCAX)vs › | $1.09B | N/A | N/A | N/A | N/A |
| STAAR Surgical Company (STAA)vs › | $1.11B | 4.43% | 1.74% | 1.95% | 1.61% |
| IRadimed Corporation (IRMD)vs › | $1.08B | 2.88% | 2.50% | 3.22% | 3.22% |
| OPKO Health, Inc. (OPK)vs › | $1.12B | N/A | 7.38% | 6.98% | 5.84% |
| Harrow Health, Inc. (HROW)vs › | $1.13B | N/A | 2.54% | 1.69% | 1.63% |
| Amphastar Pharmaceuticals, Inc. (AMPH)vs › | $1.13B | 11.26% | 12.87% | 11.35% | 9.45% |
| Avalyn Pharma Inc. Common Stock (AVLN)vs › | $1.13B | N/A | N/A | N/A | N/A |
| Teladoc Health, Inc. (TDOC)vs › | $1.05B | 7.73% | 4.52% | 2.41% | 2.41% |
| GoodRx Holdings, Inc. (GDRX)vs › | $1.15B | 12.18% | 13.63% | 7.88% | 6.04% |
EBITDA Yield = TTM EBITDA / Enterprise Value
EBITDA yield is the inverse of EV/EBITDA, expressing trailing pre-interest, pre-tax operating cash generation as a percentage of enterprise value. Comparable across leverage levels; higher is cheaper. Not meaningful for banks and insurers.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
